SCHEDULE: Coastlands Capital Takes 9.99% Stake in Camp4 Therapeutics

Coastlands Capital and its affiliates have disclosed a 9.99% beneficial ownership stake in Camp4 Therapeutics Corp, following a recent private placement.

Summary

• Coastlands Capital LP, along with its affiliates Coastlands Capital Partners LP, Coastlands Capital GP LLC, Coastlands Capital LLC, and Matthew D. Perry, has reported beneficial ownership of Camp4 Therapeutics Corp.
• The reporting persons collectively beneficially own 4,886,722 shares of Camp4 Therapeutics Corp's common stock.
• This represents a 9.99% stake in the company's common stock.
• The percentage is calculated based on 20,161,073 shares outstanding on August 5, 2025, plus an additional 26,681,053 shares issued in a private placement that closed on September 11, 2025.
• The reported securities exclude shares issuable upon exercise of a pre-funded warrant in excess of the beneficial ownership limitation of 9.99%.
• The shares are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 7

Explanation: The disclosure of a new significant institutional investor taking a substantial stake, particularly through a private placement, generally indicates confidence in the company and provides capital, which is a positive signal for the company's stability and future prospects.

Positives

• A significant institutional investor, Coastlands Capital, has taken a substantial stake in Camp4 Therapeutics, potentially signaling confidence in the company's future prospects.
• The investment is part of a private placement transaction, indicating a successful capital infusion for Camp4 Therapeutics.

Risks

• The filing itself does not detail specific risks of Camp4 Therapeutics, but the nature of a Schedule 13G implies general market risks associated with holding common stock.

Industry Context

The entry of a significant institutional investor like Coastlands Capital into Camp4 Therapeutics' shareholder base can be viewed positively, especially for a company in the biotechnology or pharmaceutical sector which often requires substantial capital. Such investments can validate a company's strategic direction or pipeline potential, potentially attracting further investor interest and providing crucial funding for research and development.

Stakeholder Impact

• Shareholders: The entry of a new significant institutional investor may be seen as a positive signal, potentially increasing investor confidence and liquidity. The private placement also resulted in dilution for existing shareholders, but provided capital to the company.
• Company (Camp4 Therapeutics): The private placement provided capital, which is crucial for research, development, and operational activities in the therapeutics sector.

Key Dates

Recommendation

While the entry of a new institutional investor and a successful private placement are positive signals, a Schedule 13G filing primarily discloses ownership and does not provide sufficient operational or detailed financial information to warrant a 'buy' or 'strong buy' recommendation. Investors should 'hold' and await further financial and operational updates from Camp4 Therapeutics to assess the long-term implications of this capital infusion and the strategic intent behind Coastlands Capital's stake.

Keywords

Camp4 Therapeutics, Coastlands Capital, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Private Placement, Institutional Investor, Biotechnology, Pharmaceuticals